Biotech Stock Mailbag: Hemispherx Biopharma
The Street (Free subscription) | yesterday
Biotech reporter Adam Feuerstein answers reader email about Hemispherx Biopharma, Cel-Sci and other stocks.
Explore : Finance
Adam Feuerstein
Your search relates to more than one category
5Vote!
1Vote!
FDA did not approve Ampligen
Tired of ME (Free subscription) | 12/02/2009
Source: The Street Date: 1 december 2009 Author: Adam Feuerstein URL: The Street Hemispherx BioPharma(HEB Quote) said late Tuesday night that the Food and Drug Administration refused to approve the experimental drug Ampligen for use in patients with chronic fatigue syndrome.
4Vote!
Hemispherx battered after FDA rejects Ampligen NDA
Fiercebiotech (Free subscription) | 12/02/2009
... slid 44 percent in extended trading last night, dropping 53 cents to 67 cents. As TheStreet 's Adam Feuerstein notes, the FDA's action amounts to a "staggering blow" capping a 20-year quest to gain an approval for the drug, which has been tested for a variety of ailments. Another late-stage trial could easily require hundreds of patients and prove to be very expensive. Its...
5Vote!
Research Firm Lays Out Surprise Bio Events for 2010: BioBuzz
The Street (Free subscription) | 11/30/2009
Stocks will move if any of these unexpected events come true.
Explore : Finance